



Your Elrexfio®[▼] (Elranatamab) Patient Alert Card

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via HPRAs Pharmacovigilance, Website: www.hpra.ie. Any suspected adverse reactions may also be reported to Pfizer Medical Information on 1800 633 363.



REMEMBER: If you have **any** of these symptoms, call your doctor or seek emergency medical attention right away! These are not all of the possible symptoms of elranatamab. Tell your doctor if you have any symptom that bothers you or does not go away.

This card has been given to you because you have already received, or will receive, treatment with elranatamab. Elranatamab is a medication for people with certain types of multiple myeloma.



You should remain within proximity of a healthcare facility, and be monitored for signs and symptoms for 48hrs after administration of the first 2 step-up doses.

ALWAYS CARRY THIS CARD WITH YOU. SHOW THIS CARD to any healthcare provider involved in your care and if you go to the hospital, including the Accident & Emergency Unit.



IMPORTANT SAFETY INFORMATION FOR PATIENTS RECEIVING TREATMENT WITH ELRANATAMAB

Elranatamab can cause Cytokine Release Syndrome (CRS), and neurologic toxicity, including Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS), which may be fatal or life threatening.


Patient name: _____

_____ has received elranatamab.

Name of treating Haematologist: _____

Office phone: _____

After hours phone: _____



Dates of elranatamab injections:

■ Step-up dose 1: _____

■ Step-up dose 2: _____

■ First full dose: _____

Call your healthcare provider or get emergency help right away if you have **any** of these symptoms:

- Fever (38°C or higher)
- Trouble breathing
- Chills
- Dizziness or light-headedness
- Fast heartbeat
- Headache
- Agitation, trouble staying awake, confusion or disorientation, seeing or hearing things that are not real

For more information, please see the full elranatamab patient information leaflet, summary of product characteristics, or email Pfizer Medical Information at medical.information@pfizer.com or call Pfizer Medical Information on 1800 633 363.

- Trouble speaking, thinking, remembering things, paying attention, or understanding things
- Problems walking or muscle weakness
- Shaking (tremors), loss of balance, or muscle spasms
- Numbness and tingling (feeling like “pins and needles”)
- Burning, throbbing, or stabbing pain
- Changes in your handwriting

WARNING
Dear Healthcare Provider, Please be aware that this patient is receiving ELREXFIO®[▼] (Elranatamab)

Developed by 

Job code: PP-E1A-IRL-0001
Date of preparation: JAN2024